Comparing the associations between host and tumor factors with survival outcomes with anti‐PD‐1 immunotherapy in metastatic melanoma

Abstract Background Anti‐programmed death‐1 (PD‐1) immunotherapy has drastically improved survival for metastatic melanoma; however, 50% of patients have progression within 6 months despite treatment. In this study, we investigated host, and tumor factors for metastatic melanoma patients treated wit...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kim Koczka, Rodrigo Rigo, Eugene Batuyong, Sara Cook, Mohammad Asad, Isabelle Vallerand, Aleksi Suo, Edwin Wang, Tina Cheng
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2023-02-01
Edice:	Cancer Medicine
Témata:	melanoma prognostic survival and immunotherapy
On-line přístup:	https://doi.org/10.1002/cam4.5070
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!